No Data
No Data
No Data
No Data
No Data
Life Science Cares Launches in Switzerland
ZURICH, Switzerland, April 19, 2024 (GLOBE NEWSWIRE) -- Today, Life Science Cares, a collective effort of the life science industry to reduce the impact of poverty and inequality in their communities, launched in
GlobeNewswireApr 19 23:12
Molecular Partners Announces All Board Proposals Approved at the Annual General Meeting
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., April 17, 2024 (GLOBE NEWSWIRE) -- Molecular Partners AG ((SIX: MOLN, NASDAQ:MOLN), a clinical-stage biotech company developing a new class of custom-built protein
GlobeNewswireApr 17 23:12
Molecular Partners Publishes Invitation to Annual General Meeting 2024
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 26, 2024 (GLOBE NEWSWIRE) -- Molecular Partners AG ((SIX: MOLN, NASDAQ:MOLN), a clinical-stage biotech company developing a new class of custom-built protein
GlobeNewswireMar 26 21:26
Earnings Call Summary | Molecular(MOLN.US) Q4 2023 Earnings Conference
The following is a summary of the Molecular Partners AG (MOLN) Q4 2023 Earnings Call Transcript:Financial Performance:Molecular Partners reported an annual revenue of CHF7 million for 2023, with CHF4
Futu NewsMar 15 23:26 · Conference Call
Molecular Partners FY 2023 GAAP EPS $(2.13) Misses $(2.00) Estimate, Sales $7.894M Beat $5.333M Estimate
Molecular Partners (NASDAQ:MOLN) reported quarterly losses of $(2.13) per share which missed the analyst consensus estimate of $(2.00) by 6.6 percent. The company reported quarterly sales of $7.894 m
BenzingaMar 15 04:11
Molecular Partners To Hold Conference Call to Discuss Fourth Quarter and Full Year 2023 Results and Announces Upcoming Investor Presentations
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 01, 2024 (GLOBE NEWSWIRE) -- Molecular Partners AG ((SIX: MOLN, NASDAQ:MOLN), a clinical-stage biotech company developing a new class of custom-built protein
GlobeNewswireMar 2 05:00
No Data
No Data